Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41574-023-00938-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective.
Liver Int
January 2025
Depatrtment of Medicine, Karsh Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), parallels the rise in sedentary lifestyles. MASLD is the most common form of steatotic liver disease (SLD), which represents the umbrella beneath which the vast majority of chronic liver diseases fall, including alcohol-related liver disease and their overlap. These conditions are the leading contributors to chronic liver disease, significantly impacting global morbidity and mortality.
View Article and Find Full Text PDFRecent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.
Gut
November 2024
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria.
Article Synopsis
- There is a significant need for effective drug treatments for metabolic dysfunction-associated liver diseases, specifically MASLD and its more severe form, MASH.
- GLP-1 receptor agonists, already approved for diabetes and obesity, have shown promise in early clinical trials for treating MASLD/MASH, leading to further testing in phase 3 trials.
- Newer therapies involving various incretin receptor agonists are emerging as potential solutions, particularly for patients who also have obesity or diabetes, with evidence suggesting they may help improve liver health and related complications.
Recent achievements and future directions of anti-obesity medications.
Lancet Reg Health Eur
December 2024
Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany.
Article Synopsis
- Recent advancements in pharmacological treatments for obesity, particularly with GLP-1 agonists and unimolecular peptides, have shifted the perception of obesity management from 'Mission Impossible' to a more feasible approach with promising results.
- These novel treatments not only aid in weight loss and blood sugar control for those with obesity and type 2 diabetes, but also show potential benefits for other health issues like neurodegenerative diseases and cardiovascular conditions.
- The review discusses the progress made in incretin-based therapies, their effectiveness and safety, as well as limitations and side effects associated with their use.
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity.
Annu Rev Physiol
November 2024
2Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; email:
Driven by increased caloric intake relative to expenditure, obesity is a major health concern placing economic and operational strain on healthcare and social care worldwide. Pharmacologically, one of the most effective avenues for the management of excess adiposity is the suppression of appetite. However, owing to the body's natural physiological defense to weight loss and tolerability issues that typically accompany anorectic agents, leveraging this approach to induce sustained weight loss is often easier said than done.
View Article and Find Full Text PDFAchieving equitable access to incretin-based therapies in cardiovascular care.
Am Heart J Plus
October 2024
Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with significant cardiovascular (CV) benefits. Despite the clinical efficacy of incretin-based therapies, high costs, suboptimal access, limited insurance coverage, and therapeutic inertia present substantial barriers to widespread adoption. Overcoming these obstacles is essential for the equitable initiation, access, and utilization of incretin-based therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!